Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 2
Opinion
Video
Utility of Molecular Testing in Skin Cancer Risk Assessment
Author(s):
An expert discusses the qualities of genetic tests that are most important to clinicians seeking precise and reliable results for melanoma diagnosis and prognosis, and reviews the 31-gene expression profile (GEP) test, highlighting its ability to classify melanoma risk into 1A, 1B, 2A, and 2B, with 1A patients showing higher melanoma-specific survival (MSS) and overall survival (OS), while 1B/2A and 2B classifications serve as independent predictors of MSS and OS, noting that patients who underwent 31-GEP testing had lower mortality compared with untested patients.
Video content above is prompted by the following:
- Various gene expression profiles have been studied for the diagnosis of melanoma (such as the 2- or 3-GEP pigmented lesion assay) as well as for melanoma prognosis (including the 31-GEP and 8-GEP tests). Biomarkers, including lactate dehydrogenase and circulating tumor DNA (ctDNA) have also been investigated in melanoma classification strategies. What qualities of a particular genetic test are most important to clinicians seeking precise and reliable results?
- Discuss the following GEP/biomarker tests for melanoma:
- 31-GEP test
- Classifies risk into 1A, 1B, 2A, or 2B
- 1A patients have a higher MSS and OS compared with 1B/2A and 2B
- 1B/2A and 2B classification were independent predictors of MSS and OS
- Patients who underwent 31-GEP testing had lower MSS mortality and overall mortality when compared with untested patients
Related Videos
Related Content
